Trump's Shock Move: 30-Day Ultimatum to Lower Drug Prices

Trump's Executive Order Targets High Drug Prices in the US Washington, D.C. – In a move that has sent ripples through the pharmaceutical industry, President Trump has issued an executive order aimed at drastically reducing the cost of prescription drugs in the United States. The order, announced on May 13th, 2025, mandates that pharmaceutical companies lower their prices to match those in other countries within 30 days. Failure to comply will result in unspecified federal action. While the specifics of the plan remain somewhat vague, speculation abounds. Some suggest the administration will engage in direct negotiations with pharmaceutical companies to secure lower prices. Others believe the strategy will involve increased imports of cheaper drugs from other nations. "This is a bold step to address the outrageous cost of prescription drugs," said a senior administration official, speaking on condition of anonymity. "The American people deserve affordable healthcare, and this executive order is a crucial step in that direction." The pharmaceutical industry has responded cautiously, with several companies stating that they are reviewing the executive order and assessing its implications. Concerns have been raised about the potential impact on research and development, as well as the complexity of implementing such a sweeping policy. The coming weeks will be critical in determining the success of this initiative. The order's impact on drug prices and the healthcare system as a whole remains to be seen, but it marks a significant attempt by the Trump administration to address a long-standing issue of concern for many Americans.